| Renal cell carcinoma treatment | Lifetime | 276 | US 157 | 98.68 |
| Prostate Cancer Treatment and Research | Lifetime | 493 | US 269 | 98.59 |
| Renal and related cancers | Lifetime | 561 | US 287 | 97.46 |
| Cancer Diagnosis and Treatment | Lifetime | 668 | US 306 | 96.87 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 652 | US 321 | 98.01 |
| Cancer, Lipids, and Metabolism | Lifetime | 817 | US 381 | 97.18 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 778 | US 309 | 96.57 |
| Ferroptosis and cancer prognosis | Lifetime | 601 | US 142 | 94.36 |
| Bladder and Urothelial Cancer Treatments | Lifetime | 905 | US 393 | 96.87 |
| Multiple and Secondary Primary Cancers | Lifetime | 500 | US 224 | 95.29 |
| Economic and Financial Impacts of Cancer | Lifetime | 530 | US 336 | 94.86 |
| PARP inhibition in cancer therapy | Lifetime | 550 | US 253 | 94.14 |
| Renal cell carcinoma treatment | 2021-2025 | 12 | US 6 | 99.61 |
| Prostate Cancer Treatment and Research | 2021-2025 | 18 | US 7 | 99.84 |
| Cancer Genomics and Diagnostics | 2021-2025 | 53 | US 26 | 99.47 |
| Prostate Cancer Diagnosis and Treatment | 2021-2025 | 33 | US 12 | 99.38 |
| Renal and related cancers | 2021-2025 | 21 | US 10 | 99.02 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 45 | US 16 | 98.69 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 209 | US 84 | 99.19 |
| PARP inhibition in cancer therapy | 2021-2025 | 47 | US 21 | 98.44 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 66 | US 23 | 98.09 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 123 | US 51 | 98.45 |
| Hormonal and reproductive studies | 2021-2025 | 46 | US 7 | 97.00 |
| Cancer Diagnosis and Treatment | 2021-2025 | 96 | US 25 | 93.24 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 129 | US 79 | 95.52 |
| COVID-19 and healthcare impacts | 2021-2025 | 605 | US 198 | 91.95 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 212 | US 81 | 85.54 |
| Genetic factors in colorectal cancer | 2021-2025 | 868 | US 281 | 87.08 |
| Urinary and Genital Oncology Studies | 2021-2025 | 667 | US 207 | 85.43 |
| Science, Research, and Medicine | 2021-2025 | 224 | US 74 | 38.28 |
| Glutathione Transferases and Polymorphisms | 2021-2025 | 564 | US 92 | 29.86 |
